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Abstract
Background: The microorganism present in breast milk, added to other factors, determine the colonization of
infants. The objective of the present study is to evaluate the safety, tolerance and effects of the consumption of a
milk formula during the first year of life that is supplemented with L. fermentum CECT5716 or Bifidobacterium breve
CECT7263, two strains originally isolated from breast milk.
Methods: A randomized, double blind, controlled, parallel group study including healthy, formula-fed infants was
conducted. Two hundred and thirty-six 1-month-old infants were selected and randomly divided into three study
groups according to a randomization list. Infants in the control group received a standard powdered infant formula
until 12 months of age. Infants in the probiotic groups received the same infant formula but supplemented with L.
fermentum CECT5716 Lc40 or B. breve CECT7263. Main outcome was weigh-gain of infants as safety marker.
Results: One hundred and eighty-nine infants completed the eleven months of intervention (61 in control group,
65 in Lf group and 63 in Bb group). The growth of infants in the three groups was consistent with standards. No
significant differences were observed in the main outcome, weight-gain (Control group: 5.77 Kg ± 0.95, Lf group:
5.77 Kg ± 1.31, Bb group: 5.58 Kg ± 1.10; p = 0.527). The three milk formulae were well tolerated, and no adverse
effects were related to the consumption of any of the formula. Infants receiving B. breve CECT7263 had a 1.7 times
lower risk of crying than the control group (OR = 0.569, CI 95% 0.568–0.571; p = 0.001). On the other hand, the
incidence of diarrhoea in infants receiving the formula supplemented with L. fermentum CECT5716 was a 44%
lower than in infants receiving the control formula (p = 0.014). The consumption of this Lactobacillus strain also
reduced the duration of diarrhoea by 2.5 days versus control group (p = 0.044).
Conclusions: The addition of L. fermentum CECT5716 Lc40 or B. breve CECT7263, two probiotic strains naturally
found in breast milk, to infant formulae is safe and induces beneficial effects on the health of infants.
Trial registration: The trial was retrospectively registered in the US Library of Medicine (www.clinicaltrial.gov) with
the number NCT03204630. Registered 11 August 2016.
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Background
Breast milk contains physiological microbiota, which
contributes to colonization in infants [1, 2]. The micro-
organisms present in breast milk, as well as the prebiotic
factors included in it, determine the colonization of in-
fants and contribute to the differences found between
the microbiota of formula-fed and breast-fed infants [3].
Correct, early colonization is a key factor in the process
of maturation of infants during the first months [4]. In
this sense, studies showing that the first contact with mi-
croorganisms triggers a cascade of reactions that are
crucial for infant immune system maturation have been
particularly relevant [5, 6]. In fact, exposition to micro-
bial dysbiosis early in life has been associated with
diseases related to the dysfunction of the immune re-
sponse, such as allergies [7, 8], type 1 diabetes [9], celiac
disease [10] and inflammatory bowel disease [11]. Be-
cause of the importance of early colonization on the fu-
ture health of infants, several strategies to modulate
infant colonization are being used in infant nutrition.
One of these strategies is the supplementation of infant
formula with probiotic microorganisms and prebiotic
factors, such as galacto oligosaccharides.
In this context, the use, in infant formula, of bacterial
strains originally found in the breast milk of healthy
women seems to be a coherent strategy to supply to the
formula-fed infants with microorganisms that are natur-
ally provided to breast-fed infants. In line with this strat-
egy, two clinical trials were previously performed in
infants with Lactobacillus fermentum CECT5716, a pro-
biotic strain originally isolated from breast milk. The
studies demonstrated the safety of the probiotic strain,
even long term [12, 13]. Moreover, the administration of
the strain was associated with a lower incidence of
gastrointestinal infections in the infants during the
period of intervention, which was corroborated in the
two clinical trials performed in the infant population
[12, 14].
While it is true that Lactobacillus is a common inhab-
itant in an infant’s intestine, the genus Bifidobacterium
is one of the most abundant, especially in breast-fed in-
fants [15, 16]. Bifidobacterium has been associated with
beneficial effects on immune and intestinal function [17,
18]. Since Bifidobacterium spp are also found in breast
milk, the addition of Bifidobacterium strains to infant
formula adheres to the strategy to supply formula-fed in-
fants with strains naturally found in breast milk.
To date, a large number of studies have been carried
out in this field with very positive results for some of the
strains analysed. However, experts still think that more
evidence is needed [19, 20]. The objective of the present
study is to evaluate the safety, tolerance and effects of
the consumption of milk formula supplemented with
strains originally isolated from breast milk, L. fermentum
CECT5716 or Bifidobacterium breve CECT7263, during
the first year of life.
Methods
Study design and medical centers
This is a randomized, double blind, controlled, parallel
study with three groups developed in the Paediatrics de-
partment of two Spanish hospitals, Hospital Virgen de
las Nieves (Granada, Spain) and Hospital Reina Sofía
(Córdoba, Spain), two private paediatric clinics (Roque-
tas de Mar, Almería (Spain) and “Cristo de la Salud”,
Granada (Spain)), and 7 public paediatric health centers
(Andalusian Health Service, Granada (Spain)).The study
adheres to CONSORT guidelines and was retrospect-
ively registered in the US Library of Medicine (www.
clinicaltrial.gov) with the number NCT03204630.
Participants and criteria of inclusion
Healthy infants one-month of age who were exclusively
feeding with infant formula were included in the study
after the parents or caregivers gave written consent. Sub-
jects were excluded from the study if they had a history
of mild or serious gastrointestinal disorders (gastro-
esophageal reflux, history of chronic diarrhoea or consti-
pation), gastrointestinal surgery, metabolic disorders
(lactose intolerance, diabetes), cow’s milk protein allergy,
immune deficiency, antibiotic prescription one-week
before inclusion and prior use of probiotic-containing-
infant formula.
Sample size calculation
The variable for the calculation of the sample size was
the primary outcome, which was the average weight gain
of infants between baseline and 120 ± 3 days of age. Tak-
ing into account several safety studies in which growth
was considered the primary outcome [21, 22] and in ac-
cordance with the Scientific Committee for Food Report,
the study was designed to have power to detect a differ-
ence in weight gain equal to 0.5 standard deviations
[23]. Therefore, it was calculated that 63 children would
be required in each formula group with a significance
level of 5% and a power of 80% (two-sided test). In order
to compensate for drop outs during the intervention, the
sample size was increased by 25%. Statistical computa-
tions in R was performed to calculate sample size
needed to test interactions: One formulation was based
on the formula proposed per Lu et al. [24] for analysing
repeated measures with missing data, and for the 5%
level, 80% power and progressively missing 20% of re-
sponses and the total sample size per treated group of
76 participants were needed (library longpower from R).
The second calculation was performed regarding the
sample sized need for obtaining regression coefficients
in multiple regression [25]. The implementation of the
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calculation was performed in R using the library MBESS,
and the results obtained was a total of 34 participant per
regression coefficient.
Randomization and blinding
Infants included in the study were randomly allocated into
three study groups by using the computer program
(SIGESMU®). According to the randomization list each re-
cruiter center received batches of infant formula labelled
with the corresponding numbers. Each volunteer received in
each visit a batch of infant formula contained enough for-
mula for the next 3months until the next paediatrician visit.
The infant formulae were supplied by Lactalis-Puleva (Gran-
ada, Spain) in indistinguishable plain white tins. The blind-
ing of the trial was ensured by a sensorial test of the three
formulas by an expert panel that concluded the three prod-
ucts were identical. Paediatricians, parents and researchers
only knew the volunteer’s code, not knowing which group
belonged. The list of randomization was revealed once the
study was completed and the code of each group once the
statistical analysis of the data was performed.
Products of the study and guidelines of consumption
The control formula was a standard powdered infant for-
mula with a nutritional composition in accordance with
current EU regulations for both starter and follow-on for-
mula. Probiotic groups received the same formula but sup-
plemented with L. fermentum CECT5716 Lc40 in case of Lf
group or B. breve CECT7263 in case of Bb group. In both
cases the concentration dose of probiotic strain was107 cfu/
g The concentration of the probiotic in the formula was
analysed and confirmed every 6months. Formulae were
consumed by the infants from 1month of age until the age
of 12months (intervention period). The paediatricians pre-
scribed the amounts of formula per day to be administered
to the infants and the guidelines for complementary feeding
according to current ESPGHAN guidelines [26].
Study outcomes and data collection
Average weight gain between baseline (1month of age)
and 4months of age was the primary outcome of the
study. Secondary outcomes included average weight,
length and head circumference, incidence of intestinal in-
fections, feeding-related behaviour, adverse effects associ-
ated with formula consumption and faecal microbiota.
The follow-up visits to the paediatrician were performed
at baseline and at the ages of 2, 4, 6, 9 and 12months.
The paediatrician made the diagnosis of infectious dis-
eases according to specific symptoms and standardized
definitions. Gastrointestinal infection was characterized by
occurrence of loose or watery stool ≥3 times/day with or
without a fever or vomiting [27], and respiratory tract in-
fections were determined in case of presence of abundant
mucosity and/or cough during two or more days in a row
with or without a fever or the presence of wheezing and/
or crepitant with or without fever. Parents received a diary
to collect data about incidences in the health of the infants
and unscheduled visits with a doctor. Moreover, they re-
ceived a notebook with questionnaires to be completed
every two weeks, in which information regarding the daily
number of depositions, behaviour and gastrointestinal dis-
comfort were recorded (Table 1).
Four faecal samples were collected simultaneously
from every infant at baseline and 4, 6, 9 and 12 months
of age, maintained at − 20 °C and processed within
4-weeks. Of the four samples, three were used for
parameters determination, and the last one was stored
at − 80 °C.
Faecal bacteria quantification
Lactobacillus spp., Bifidobacterium spp., Clostridium
spp., Bacteroides spp. and Escherichia coli counts were
measured by quantitative polymerase chain reaction.
The ATP™ GENOMIC DNA MINI KIT (TISSUE)
AGT300 (ATP Biotech Inc., Taipei City 10,683, Taiwan)
Table 1 Feeding related parameters
During the last 2 days the number of fecal depositions/day 1 = < 1 time, 2 = 1–3 times, 3 = 4–6 times, 4 = 7–10 times, 5= > 10 times
During the las 2 days the feces color was 1 = yellow 2 =mustard 3 = brown 4 = grey 5 = green
During the last 2 days the consistency of feces was 1 = hard lumps, 2 = sausage with cracks, 3 = soft sausage, 4 =mushy
(like porridge),5 = watery
During the last 2 days the infant suffered flatulency 1 = 0 h 2 = < 3 h/day 3 = 3-6 h/day 4 = 6-12 h/day 5= > 12 h/day
During the last 2 days the infant suffered regurgitation 1 = not at all, 2 = regurgitation of small amounts during or shortly after
feeding, 3 = larger regurgitation during or shortly after feeding, 4 =minor
vomiting with time-lag to prior feeding, 5 = severe vomiting with
considerable loss of fluid
During the past 2 days the total sum of sleeping hours in 24 h
was on average
1 = < 11 h/day, 2 = 11-14 h/day, 3 = 14–17 h/day, 4 = 17–20 h/day,
5= > 20 h/day
Gender Temper: The infant’s behavior when awake during the last
2 days is best described as
1 = tired, passive, 2 = quiet, watching, 3 = well-balanced, active, 4 =
bubbly, fidgety, exited, 5 = disturbed, agitate
Colic symptoms: during the last 2 days the infant has suffered
continuous and disconsolate crying episodes
1 = not at all, 2 = < 3 h/day, 3 = 3–6 h/day, 4 = 6–12 h/day,
5= > 12 h/day
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was used for bacterial DNA isolation. In brief, the co-
lonic content was homogenized in Peptone Water at a
concentration of 100 mg/ml under sterile conditions,
and 200 μl of the previous suspension was added to an
Eppendorf tube (20 mg/ml) for DNA extraction follow-
ing the instructions of the ATP™ GENOMIC DNA MINI
KIT (TISSUE) AGT300 protocol.
DNA quantification was performed by qPCR using
SYBR® green as a fluorophore (Quantifast SYBR Green
OCR Kit Qiagen Cat. No 204057) and specific primers
for each group as previously described by Maldonado-
Lobón et al. [13].
Statistical analysis
Descriptive analysis and bivariate statistical tests per
treatment group were performed for baseline charac-
teristics as well as the outcomes. For this analysis,
when data were continuous and normality could be
assumed, ANOVA was performed using F when data
were homogeneous and Welch when equal variances
could not be assumed. Categorical variable percent-
ages were calculated, and differences between groups
were analysed using the chi-square test or the chi-
square exact test in the case of large contingency ta-
bles without enough cases by cells of categories. For
the outcomes related to an event, the Incidence Rate
Ratio (IRR) and Odd Ratio (OR) were calculated.
Statistical models were applied in order to analyse
the differences in the responses between treatment
groups adjusted by other covariates and factors that
may be associated to the change of the responses.
The statistical models applied to the primary and sec-
ondary outcomes were adjusted by time, age at entry,
group of treatment, sex, C-section, having siblings,
rotavirus vaccination, breastfeeding prior to interven-
tion and gestational age. Linear Mixed Models were
applied for continuous data when the residuals were
normally distributed. Poisson Mixed Models were ap-
plied when the data recorded were related to the
number of events observed, and Logistic Mixed
Models were applied when the outcomes to be ana-
lysed were binary responses.
Ordinal logistic regression mixed models were ap-
plied to the responses of secondary outcomes over
time and adjusted by relevant covariates. Ordinal out-
comes were, for example, stool frequency, consistency,
colic and flatulence, regurgitation symptoms and
sleeping hours. Additionally, a multinomial logistic re-
gression mixed model was applied for nominal data,
such as faeces colour.
The statistical software used to perform the analysis
was R version 3.1. Statistical tests at the 5% significance
level (two-tailed) were considered for hypothesis testing.
Results
Population
Two hundred and thirty-six infants were included in the
study and randomized between April 2011 and July
2012. The intervention ended on June 2013. A flow
chart of participants is shown in Fig. 1. Nineteen percent
of the infants did not complete the intervention and
withdrew from the study. Causes of withdrawal were the
perception by the mother that the child did not drink
enough milk, changes to another kind of formula be-
cause of a cow milk allergy, lactose intolerance, infant
colic, reflux or constipation. Two additional infants were
excluded because they received a commercial formula
and another two infants mistakenly received the formula
corresponding to another group of the study. No differ-
ences among the groups were detected between the
number and causes of withdrawal. The data of all the in-
fants included in the study were analysed (analysis per
intention to treat, ITT). For the analysis of Incidence
Rate Ratio, in which events accumulated during the 11
months of intervention, only data of infants who com-
pleted the intervention were taken into account (per
protocol). If statistically significant differences were ob-
served, a second analysis was performed including data
of all infants in the study (ITT analysis). In this case, 189
infants who completed the intervention were included in
the analysis.
The baseline characteristics of the 236 infants included
in the study were analysed. In addition to those related
to the infants, they were included mother’s characteris-
tics, variables related to gestation and delivery, and the
environment around the infant. All these baseline char-
acteristics were comparable among the study groups
(Table 2).
Growth of infants
Based on the mean weight, length and head circumfer-
ence for boys and girls, the corresponding mean for each
group over time was represented with respect to the
standard percentile curves (Fig. 2). Growth curves for
weight, length and head circumference were very similar
in the three groups. With respect to weight, values for
the three groups remained quite close to one another,
around the 50% percentile, until 6 months. After 6
months, the means were between the 50th and 75th per-
centiles. Similar results were observed for the growth
curves of length and head circumference.
Mean weight, length and head circumference for each
group were obtained at 1, 2, 4, 6, 9 and 12months
(Table 3). Regarding weight, no significant differences
were observed among the groups at any time. To analyse
the overall effect, the linear mixed model was adjusted
by basal characteristics. The model did not show
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significant differences between groups (p = 0.427 (Lf vs
Control); p = 0.296 (Bb vs Control)). Moreover, no sig-
nificant differences were detected in the primary out-
come, mean weight gain from 1 to 4months of age
(Control group: 2.67 ± 0.70 Kg; CI 95% 2.50–2.82, Lf
group: 2.79 ± 0.79 Kg; CI 95% 2.60–2.98, Bb group:
2.76 ± 0.71 Kg; CI 95% 2.58–2.93; p = 0.560). Mean
weight gain from 1 to 12months was also analysed and
no significant differences among the groups were
observed (Control group: 5.77 ± 0.95 Kg CI 95% 5.53–
6.01, Lf group: 5.77 ± 1.31 Kg; CI 95% 5.44–6.10, Bb
group: 5.58 ± 1.10 Kg; CI 95% 5.31–5.85; p = 0.527).
The length of the children was similar throughout the
study among the 3 groups. However, at 4 months, in-
fants in the Lf group showed having slightly longer
length measurements than those of the control group
(p = 0.049). This difference was primarily observed in
boys (p = 0.021). The estimated parameters from the







Male/female, n (%) 41/36 (53.2/46.8) 48/35 (57.8/42.2) 39/37 (51.3/48.7)
Age at enrolment (weeks), mean ± SD 3.73 ± 0.93 3.80 ± 1.11 3.75 ± 1.19
Birth weight (kg), mean ± SD 3.21 ± 0.5 3.18 ± 0.4 3.17 ± 0.59
Delivery by cesarean (%) 27.3 26.5 32.9
Gestational age (weeks) mean ± SD 39.0 ± 1.5 39.2 ± 1.3 38.9.2 ± 1.7
Age of mother at birth (years) mean ± SD 34.41 ± 2.3 34.06 ± 1.3 33.93 ± 1.7
Breast feeding (days) mean ± SD 6.13 ± 9.6 4.06 ± 7.8 5.25 ± 8.9
Smoking during pregnancy (%) 16.7 14.5 19.2
Smoking during lactacion (%) 15.6 12.2 17.9
Smoking in the household (%) 42.9 38.6 48.7
Older siblings (%) 61.5 50.6 51.3
Weight of mother (kg) mean ± SD 70.8 ± 13.95 69.8 ± 14.2 70.7 ± 14.1
Pets at home (%) 26.0 32.5 42.1
Fig. 1 Flow chart of participants
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linear mixed model showed no differences for length
among experimental groups (p = 0.588 (Lf vs Control),
p = 0.475 (Bb vs Control)). Interestingly, a difference in
behaviour or length responses of infants born by C-
section was observed depending on the group. In the
Control group, infants born by C-section had a lower
length than infants born by natural delivery (p = 0.042).
However, in the Lf and Bb groups, infants born by C-
section had higher length responses than infants born by
natural delivery (p = 0.006 for Lf group and p = 0.018 for
Bb group).
Finally, no differences were observed in head circum-
ference values among groups (p = 0.384 (Lf vs Control;
p = 0.183 (Bb vs Control)).
Formula intake, tolerance and adverse effects
No significant differences were found among the
study groups in regard to daily intake of formula
(Table 4). The daily consumption of the formula cor-
responded to an average dosage of probiotic bacteria
of 1 × 109 cfu/day up to 6 months and 7-8 × 108 cfu/
day between 6 and 12 months.
No adverse effects associated to supplementation with
L. fermentum CECT5716 and B. breve CECT7263 were
detected during the study.
Some withdrawals were related to symptoms which
might have been related to the tolerance of the formula,
such as reflux, infant colic, constipation or low con-
sumption of the formula (Fig. 1). However, no significant
differences in the dropout rates among groups were de-
tected and incidences were in line or even below that
those in general population; therefore, symptoms could
not be related to the supplementation with L. fermentum
CECT5716 or B. breve CECT7263 and paediatricians
considered three formula of the study well tolerated.
Parameters related to tolerance and intestinal function
were also evaluated based on the questionnaire ex-
plained in methods section (Table 1).
Faecal depositions: most of the infants showed a stool
frequency of 1–3 depositions per day. In general, the
probability of an infant to have 1–3 faecal depositions/
day is 0.945; in contrast, the probability of having a fre-
quency of less than once a day is 0.095. Differences
among the groups were observed during the first month
Fig. 2 Based on the mean, by gender and group, of the weights, lengths and head circumferences of infants, the corresponding percentile for
the mean by boys and girls for each group over time are represented with respect to the standard curves. Black dots show the growth curve, on
average, for the Control group. White square curves for the Lf group and triangles for the Bb group. Each of the curves (black lines) is the
standard percentile at each point of age of the children
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of intervention (p = 0.015). For this period, in the Con-
trol group, 80% of infants showed a frequency of deposi-
tions between 1 and 3 times per day, in contrast with
57–59% of infants in the probiotic groups (Fig. 3). An
interaction with the type of delivery was observed. In-
fants born by natural delivery had a higher risk of having
lower frequency of faecal depositions when they were in
the Lf or Bv group in comparison with infants from the
Control group, whose risk was lower (OR = 0.411 for Lf
group p = 0.011; OR = 0.404 for group Bv, p = 0.009).
However, for infants born by C-section, the opposite oc-
curred. For infants born by C-section, the odds of having
stools more often was 3.07 and 1.66 times higher in the
Lf and Bb groups than in the Control group (p = 0.002
Lf vs. Control group; p = 0.022 Bb vs. control group).
Faeces colour: yellow, green or grey colours were more
likely to be observed at the beginning of the trial. As the
trial progressed, the faeces colour was more likely
brown. Brown colour was more likely to occur in infants
from the Lf and Bb groups than in infants in the Control
group (OR = 1.595 for Lf group, p = 0.002 vs. Control
group; OR = 1.639 for Bb group, p = 0.001 vs. Control
group).
Stool consistency: the percentage of infants showing
higher stool consistency increased with time (p < 0.001).
No differences were observed between the Control
group and Bb group (p = 0.270). However, the behaviour
of infants in the Lf group changed with time (p = 0.001),
and while it was observed that the risk of having softer
stools was 1.89 times lower in the Lf group than in the
control group at the beginning of the study, after four
months, this risk changed, and the odds of softer
consistency was 1.6 times higher in the Lf group than in
the Control group (p = 0.015).
Symptoms of gastrointestinal discomfort associated
with the diet were evaluated. Infants born by C-section
had a higher risk of suffering from more flatulence in
comparison with infants born by natural delivery (OR =
2.022; p = 0.038). As the study progressed, the risk of
suffering from flatulence decreased in all of the groups;
however, for the Lf group, the decrease throughout the
study was more pronounced (OR = 0.658; p = 0.038). At
Table 4 Formula intake corresponding to amount of milk (mL) reported by parents to be consumed by the infants for each time is
showed
INTAKE FORMULA-FED (mL) 2 months 4 months 6 months 9 months 12months
Control group Mean 783.659 883.784 730.290 618.750 552.580
SD 178.112 215.256 273.280 289.056 271.821
95% CI 727.32–837.54 814.87–951.34 638.83–825.88 535.01–721.85 463.25–653.23
Group Lf Mean 797.241 890.000 712.140 566.150 486.800
SD 199.372 165.901 202.052 131.699 181.216
95% CI 723.46–868.61 826.7–949.25 640.01–788.85 513.86–616.53 425.21–556.8
Group Bb Mean 851.250 895.517 707.590 567.590 532.220
SD 211.946 225.730 223.442 135.330 170.166
95% CI 784.75–931.55 813.82–984.11 633.1–794.13 516.13–622.4 472.59–598.15
p-value 0.627 0.603 0.988 0.998 0.351
Fig. 3 Proportions in each group of infants showing < 1 faecal deposition/day (white), 1–3 faecal depositions/day (grey) or > 3
faecal depositions/day
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the beginning of the study and during the first two
months, more than 70% of infants suffered from regurgi-
tation, which was mild in most cases. As the study
progressed over time, the frequency of regurgitation de-
creased to around 5% at the end of intervention
(p = 0.000). No differences were observed among groups.
Some variables related to the behaviour of infants were
analysed. Data about the daily hours of crying were col-
lected. In general, infants receiving B. breve CECT7263
had 1.7 times lower risk of long episodes of crying along
the study than did infants in the Control group (OR =
0.569 CI 95% 0.568–0.571; p = 0.001). Because a symp-
tom of infant colic is daily crying lasting more than 3 h,
the frequency of infants crying more than 3 h was ana-
lysed (Fig. 4). At the beginning of the study, approxi-
mately 16% of infants cried more than 3 h/day. At 6
weeks, a maximum percentage of 29% was observed in
the Control group, versus 21% in the Lf group (p =
0.335) and 12% in the Bb group (p = 0.022). The fre-
quency of infants suffering from infant colic symptoms
decreased to below 2% at 4 months of age, with no dif-
ferences between groups after that age.
Hours of sleep during the night were similar in all
the groups. The total hours of sleep per day were
similar between the Bb group and the Control group
(p = 0.927). The behaviour of the Lf group was differ-
ent compared to the Control group (OR = 0.457; p =
0.028), but the effect was dependent on the age of
the infants (p = 0.001). At the beginning of the study,
infants in the Lf group had lower odds of sleeping
more hours per day, but, at the end of the study, they
had higher odds (OR = 2.828; p = 0.007). No differ-
ences were found in the level of activity of infants
upon waking (p = 0.674 for Lf vs. Control group and
p = 0.420 for Bb vs. Control group).
Infant’s health
The most common infection during the first year of life
of infants in this study was upper respiratory infections
(83.4% of infants suffered at least one event). No differ-
ences were detected among the groups in incidence of
respiratory infections affecting the upper or lower tract
(Table 5). However, for infections affecting the upper re-
spiratory tract, the adjusted results from the multivariate
model showed an effect of smoking habits of the
mothers during pregnancy in the Control group. Thus,
the incidence of upper respiratory tract infections was
significantly higher in cases of smoking women (IRR =
1.996 CI 95% 1.366–2.860; p = 0.000). In cases of infants
from smoking mothers, the incidence of these respira-
tory infections in infants in the Lf and Bb groups was
significantly lower than the incidence in the Control
group (IRR = 0.503 CI 95% 0.274–0.899 and p = 0.023 for
Lf group; IRR = 0.479; CI 95% 0.269–0.844 and p = 0.011
for Bb group). An effect of type of birth was also de-
tected. In infants born by C-section the incidence of
upper respiratory infections was lower in Lf group than
in control group (IRR = 0.492; CI 95% 0.294–0.815; p =
0.006). In case of Bb group the effect did not reach to be
statistically significant although a trend was observed
(IRR = 0.630; CI 95% 0.372–1.062; p = 0.084).
Regarding to gastrointestinal infections, 39% of the in-
fants suffered at least one event of diarrhoea. Logistic re-
gression mixed model analysis showed a general increase
in the risk of diarrhoea throughout the study (p < 0.001)
and 2.5 times higher odds of diarrhoea in infants attend-
ing kindergarten (p = 0.005). No differences were de-
tected in the incidence of diarrhoea between the Bb
group and the Control group. However, the consump-
tion of L. fermentum CECT5716 significantly reduced
the incidence of diarrhoea by 44% in comparison with
Fig. 4 Incidence of infant crying > 3 h per day
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the Control group (IRR 0.559; CI 95% 0.326–0.938; p =
0.014) (Table 5). Analysis including the data of all in-
fants, while they had not completed the study, showed
similar results (IRR = 0.587; CI 95% 0.351–0.961; p =
0.037). No differences were observed in the risks of hav-
ing at least 1 event of diarrhoea (OR = 0.86; CI 95%
0.41–1.77; p = 0.732) but were observed in the risk of
having more than 1 event of diarrhoea, which was 14
times lower in the Lf group than in the Control group
(OR = 0.07; CI 95% 0–0.54; p = 0.002). The beneficial ef-
fect of L. fermentum CECT5716 on diarrhoea was also
observed in the duration of the events. The mean dur-
ation of diarrhoea in the Control group was 7.10 ± 4.9
days (CI 95% 5.25–8.95), while in the Lf group, the mean
duration of diarrhoea was 4.55 ± 3.6 days (CI 95% 2.95–
6.14) (p = 0.044). No differences were observed in the
duration of diarrhoea in the Bb group (6.24 ± 4.7 days;
CI 95% 4.57–7.91; p = 0.482 in comparison with the
Control group).
No significant differences were observed in the inci-
dence of other infectious diseases (otitis, conjunctivitis
and urinary tract infections), febrile episodes and derma-
titis (Table 5).
Faecal microbiota
Some of the most representative bacterial genera were
studied (Table 6). The abundance of Lactobacillus in
faeces was higher for the first months and decreased
with time (p = 0.000). Infants in the Lf group had signifi-
cantly higher values of Lactobacillus in their faeces in
comparison to the Control group (p = 0.000) and Bb
group (p = 0.024). At 4 months of age, infants in the Bb
group showed higher levels of Lactobacillus in their fae-
ces (p = 0.000), but differences were not observed in later
measurements. Regarding Bifidobacterium, a general in-
crease over time was observed (p = 0.000). In the case of
the Bb group, no differences were observed between
bacterial load in faeces of infants in the Bb group and
those of the Control group (p = 0.085). For the Lf group,
a lower load of Bifidobacterium was observed at 4
months (p = 0.038), but no significant differences were
observed at later times. A higher load of Bifidobacterium
in faeces was related to a lower risk of diarrhoea (OR =
0.767 CI 95% 0.608–0.976; p = 0.027).
A general increase in Clostridium load in faeces was
observed with time (p = 0.000). A significant difference
was observed between the Bb group and the Control
group, with infants in the Bb group having a higher level
of Clostridium in their faeces (p = 0.026). Clostridium
load in infants attending kindergarten was significantly
lower (p = 0.009), but it did not change the effect of the
treatment. It was observed that Clostridium load in fae-
ces was significantly associated with a reduction of the
risk for dermatitis for all groups (p = 0.010), meaning in-
fants with higher levels of Clostridium had a lower risk
of developing dermatitis. With respect to Bacteroides, in-
creasing values of bacteria with time were observed in
all groups (p = 0.000). Infants in the Lf group had higher
values of Bacteroides than infants in the Control group
(p = 0.044). A decrease in the load of Escherichia coli
was also detected with time (p = 0.000). Values of E. coli
in faeces were comparable among the groups (p = 0.806
Table 5 Incidence of infectious disease, febrile episodes and dermatitis during the intervention period
Number of events (N) Incidence Rate
(Standard Error)





































































































aOf the 42 diarrhea events in the control group, 19 occurred before 6 months and 23 in the period of 6 to 12 months. In the case of the Lf group, of the 25
diarrhea events 8 took place before 6months and 17 in the period of 6 to 12months
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for the Control group vs. Bb group; p = 0.089 for the
Control group vs. Lf group).
Discussion
The effects and safety of the two probiotic strains origin-
ally isolated from breast milk have been studied in the
present trial in infants. Determination of growth of in-
fants is the single most valuable component of the clin-
ical evaluation of an infant formula [28, 29]. The analysis
of the curves of growth for weight, length and head cir-
cumference by age showed similar values for the three
groups. Moreover, the values of three groups were com-
parable for the standards of growth based on healthy in-
fants published by the World Health Organization [30],
indicating the nutritional sufficiency and safety of the
experimental formula. Although, in general, the growth
of infants was similar in the three groups, at 4 months a
higher length was observed in infants in the Lf group.
However, the difference was not detectable in the mea-
surements carried out in the subsequent months. In
previous studies, a certain effect of L. fermentum
CECT5716 on the length of infants who received the
probiotic strain up to 6 months of age was also observed
[12]. Although, the difference was not sustained, and the
length of the children at 3 years of age was similar to a
control group [13]. The effect was not observed in a
third study performed in infants who received the pro-
biotic strain from 6 to 12 months of age [14]. The effects
of probiotic strains on growth of infants have been ob-
served for some strains [31, 32]. It has been proposed
that the activity of the bacteria on mucosal physiology
might influence the absorption of nutrients, as well as
metabolic and endocrine functions [12, 33]. Even so,
more studies should be performed in order to investigate
the mechanisms involved. Interestingly, it was observed
that the negative effect on length of C-section was coun-
teracted by L. fermentum CECT5716 and B. breve
CECT7263. C-section, which involves preventive anti-
biotic treatment for the woman, affects infant gut
colonization [34]. It has been previously hypothesized
that certain probiotics may prevent or attenuate the ad-
verse effects of antibiotics on gut communities, thereby
stabilizing gut integrity and improving the absorption of
nutrients [33]. Therefore, the effects observed in our
study might be related to the modulation of gut micro-
biota by the probiotic strains.
Continuing with the evaluation of the tolerance of the
probiotic formula, the data regarding the daily intake of
formula and the presentation of gastrointestinal symp-
toms, such as reflux, constipation or flatulence, demon-
strated that both probiotic formulas were well tolerated.
Interestingly, during the evaluation of the behaviour of
infants, it was detected that infants receiving the Bb for-
mula had significantly lower risk of crying than did the
control group. Infantile colic is a benign, self-limiting
process in which a healthy infant has paroxysms of in-
consolable crying. The standard diagnostic criteria is
based in crying time more than three hours per day,
more than three days per week, for longer than three
weeks [35]. It affects approximately 10 to 40% of infants
worldwide and peaks at around six weeks of age. Symp-
toms resolve usually by three to four months. In our
study, a maximum percentage of infants crying more
than 3 h/day was observed at 6 weeks (29%); however,
this percentage was reduced to 12% in the group receiv-
ing the Bifidobacterium strain. Although the cause of in-
fantile colic has not been totally elucidated, alterations
in faecal microflora, intolerance to cow’s milk protein or
lactose, gastrointestinal immaturity or inflammation, in-
creased serotonin secretion, poor feeding technique, and
even maternal smoking have been related [36]. In line
with the role of the microbiota, some probiotic strains
have been reported to reduce the crying time of infants
suffering from infantile colic [37]. As the present study
was performed with a generally healthy population, spe-
cific studies to evaluate the effect of B. breve CECT726
on infantile colic should be performed in order to cor-
roborate the possible role of this strain in reducing the
symptoms of this condition.
The most common infection during the first year of
life in the infants of this study was upper respiratory in-
fections. A beneficial effect was observed with both pro-
biotic treatments in infants born from smoking mothers.
This population, who are at a higher risk of suffering re-
spiratory infections [38], showed lower rates of incidence
in the groups consuming L. fermentum CECT5716 or B.
breve CECT7163. A higher incidence of respiratory in-
fections in infants born from smoking mothers has been
related to the adverse effects of in utero smoke exposure
on the infant’s immune system [39–41]. Because Lacto-
bacillus and Bifidobacterium are not common habitants
of upper respiratory mucosa, it seems that the effect of
the probiotic strains on the immune system might con-
tribute to the observed effect. In this sense, L. fermentum
CECT5716 was previously described to reinforce the im-
mune response by enhancing both the innate and spe-
cific immune responses [42, 43]. Recent findings have
highlighted important roles of gut microbiota on lung
immunity [44] and certain probiotic treatments have
shown efficacy in the prevention of respiratory infections
and/or reduction in the severity of the infections [45,
46]. The effect of L. fermentum CECT5716 on upper re-
spiratory infections in infants was also previously ob-
served in a study performed in infants with a follow-on
formula containing the Lactobacillus strain. In that
study, the consumption of the probiotic formula was re-
lated to a reduction in the incidence rate of upper re-
spiratory infections by 26% in comparison with the
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incidence in infants receiving a standard formula [14]. A
limitation of our study is that the effect has been ob-
served in infants born from smoking mothers, which is a
small proportion of the infants of the study.
L. fermentum CECT5716 has also been related to sig-
nificant reductions in the incidence rates of gastrointes-
tinal infections [12, 14]. In our study, a reduction of 44%
in the incidence of diarrhoea has been observed. A limi-
tation of the study is that the sample size was calculated
in order to detect differences in the weight gain of in-
fants as a safety marker. The sample size needed to de-
tect differences in the incidence of gastrointestinal
infections would be higher. However, the value of the
decrease in incidence is very similar to the 46% observed
in the Maldonado study [14]. Therefore, the results of
the present study corroborate previous ones, showing
that, in a repetitive and consistent way, the administra-
tion of this strain to infants being fed formula protects
them against gastrointestinal infections. Different mech-
anisms, such as the competitive phenomena, production
of antibacterial compounds and improvement of the im-
mune response, have been attributed to the anti-
infectious activity of probiotics and concretely to L. fer-
mentum CECT5716 [47]. The effect of the strain seems
to primarily affect repetitive infections, supporting a
probable role of the immune system. The consumption
of the probiotic strain also reduced the duration of diar-
rhoea by approximately 2.5 days with respect to the con-
trol group. There is extensive literature regarding the
efficacy of probiotics on the treatment of diarrhoea. A
systematic review, which included 56 trials, concluded
that probiotics reduced the duration of diarrhoea by a
mean of one day (24.76 h; 95% confidence interval 15.9
to 33.6 h; n = 4555); however, the size of the effect varied
considerably among studies [48]. A larger difference in
duration of diarrhoea has also been reported in another
study performed in healthy infants receiving an infant
formula containing a strain of Bifidobacterium longum
[49]. More studies are needed to determine if probiotic
use during childhood is a more efficient tool in reducing
the severity of eventual diarrhoea than the treatment
approach.
Regarding faecal microbiota, minor changes were asso-
ciated with the probiotic treatments. As previously re-
ported [14], the administration of L. fermentum
CECT5716 was associated with an increase in the faecal
load of lactobacilli. Moreover, a higher faecal load of
Bacteroidetes was observed. On the other hand, inter-
vention with B. breve CECT7263 did not affect the Bifi-
dobacterium content in faeces. The concentration of
Bifidobacterium in faeces is close to 1010 cfu/g, 3 magni-
tudes of order higher than Lactobacillus. Since the daily
ingestion of B. breve was between 7 × 108 and 1 × 109
cfus, it would be difficult to observe significant changes
in the total load of Bifidobacterium in faeces. However,
it has been previously reported that while changes in
Bifidobacterium spp. load could not be observed after
oral administration of an infant formula supplemented
with another Bifidobacterium strain, B. animalis lactis
ssp. lactis Bb12, the strain could be detected in the fae-
ces of a high percentage of infants who received the pro-
biotic formula [50]. Therefore, while B.breve CECT7263
did not induce a significant increase in faecal Bifidobac-
terium population, the strain, included as one more spe-
cies in the total microbiota, is able to affect the intestinal
and immune functions as supported by the observed ef-
fects on infant colic and respiratory infections. The
microbiota analysis in our study has been restricted to
specific bacterial groups. In order to better understand
how these probiotic strains might influence the micro-
biota of infants, a more complete microbiota analysis
should be performed.
Conclusion
Consumption of L.fermentum CECT5716 or B.breve
CECT7263 during first year of life is well tolerated and
safe. Additionally, beneficial effects of the strains con-
sumption were observed. While L. fermentum
CECT5716 stands out for its protective effects against
gastrointestinal infections, B. breve CECT7263 stands
out for its effects on the symptoms of infantile colic,
which is probably related to its effect on intestinal func-
tion. Given that both strains are found naturally in
breast milk and show beneficial activities that could
complement each other, the combination of both strains
in infant formulas could be used as a strategy to improve
the health of formula-fed infants. Since this study was
designed to demonstrate safety of the probiotic formu-
lae, new clinical trials focused in each beneficial effect
should be performed to confirm these results from the
secondary outcomes.
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